MEDISEARCHER NEWS
European Union · Medication safety · 14 November 2026
In brief
- The European Medicines Agency (EMA) has announced new advice about Mounjaro (tirzepatide) and oral contraceptives.
- Women taking the contraceptive pill are advised to use an additional barrier method for four weeks after starting Mounjaro and four weeks after each dose increase, or switch to a non-oral contraceptive method.
- The precaution reflects limited evidence about how tirzepatide may affect the absorption and effectiveness of oral contraceptives.
- The EMA’s committee adopted a healthcare-professional safety communication during its 9–12 November 2026 meeting.
- The communication will be distributed following a European Commission decision.
- Similar precautions were already recommended in the United Kingdom and Australia.
Women taking Mounjaro (tirzepatide) alongside the contraceptive pill are being advised to take additional precautions under new European medicines-regulator guidance announced on 13 November 2026.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a safety communication addressing the potential effect of tirzepatide on the reliability of oral contraceptives.
The advice is straightforward: women using oral contraception should either add a barrier method, such as condoms, for four weeks after starting Mounjaro and for four weeks after every dose increase, or switch to a non-oral contraceptive method.
The announcement is particularly relevant to women using Mounjaro for type 2 diabetes or weight management who also rely on the contraceptive pill to prevent pregnancy.
It does not mean that Mounjaro has been proven to cause contraceptive failure in every patient. Rather, European regulators are taking a precautionary approach because important uncertainties remain.
What exactly has the EMA recommended?
According to the EMA’s November 2026 committee highlights, women using an oral contraceptive while receiving tirzepatide are now advised to choose one of two approaches:
- Use an additional barrier method of contraception for four weeks after beginning Mounjaro and for four weeks after each subsequent dose increase; or
- Switch to a non-oral method of contraception following advice from an appropriate healthcare professional.
The four-week precaution applies at treatment initiation and again whenever the Mounjaro dose is increased.
It is not described as a requirement to use additional barrier contraception throughout the entire course of treatment if the patient remains on a stable dose.
However, the suitability of any contraceptive method depends on individual circumstances, including the type of contraception being used and whether pregnancy prevention is required.
When is extra contraception recommended?
| Situation | New EU advice |
|---|---|
| Starting Mounjaro | Add a barrier method for four weeks, or switch to non-oral contraception. |
| Increasing the Mounjaro dose | Add a barrier method for four weeks after each increase, or use non-oral contraception. |
| Continuing on a stable dose | The EMA announcement does not specify a new four-week precaution unless treatment is started or the dose is increased. |
| Already using non-oral contraception | The specific concern about oral contraceptive absorption does not apply in the same way. Patients should confirm that their existing method remains appropriate. |
Source: EMA CHMP meeting highlights, 9–12 November 2026. This table summarises the regulator’s advice and does not replace individual contraceptive counselling.
Why might Mounjaro affect the contraceptive pill?
Mounjaro contains tirzepatide, a medicine that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Among its effects, tirzepatide slows gastric emptying, meaning food and some medicines can take longer to move from the stomach into the intestine.
This matters because oral contraceptives must be absorbed through the digestive system.
Changes in gastric emptying can affect how quickly medicines are absorbed and, in some circumstances, how much of a medicine reaches the bloodstream.
The EMA says information remains limited on the effect of tirzepatide on the pharmacokinetics and effectiveness of oral contraceptives in women with obesity, overweight or type 2 diabetes.
Pharmacokinetics describes how a medicine is absorbed, distributed, metabolised and eliminated by the body.
Importantly, a change in the blood concentration of contraceptive hormones does not automatically establish that a contraceptive has failed. Clinical effectiveness and pharmacokinetic measurements are related but are not identical outcomes.
What have studies shown about oral contraceptive absorption?
Existing European Mounjaro product information describes a drug-interaction study involving a combined oral contraceptive containing ethinyl estradiol and norgestimate.
When the contraceptive was administered alongside a single 5 mg dose of tirzepatide, researchers observed changes in the maximum blood concentrations and overall exposure to the contraceptive hormones.
Reported reductions in maximum plasma concentration included:
- 59% for ethinyl estradiol;
- 55% for norelgestromin, an active metabolite of norgestimate; and
- 66% for norgestimate.
Overall drug exposure, measured using the area under the concentration-time curve (AUC), decreased by approximately 20% to 23% for the measured components.
The existing European product information previously described these changes as not clinically relevant and stated that no oral contraceptive dose adjustment was required.
The November 2026 safety communication represents a more precautionary position about contraceptive reliability, reflecting the remaining uncertainty about how these pharmacokinetic changes may affect protection against pregnancy in clinical practice.
These figures should not be interpreted as showing a 59%, 55% or 66% reduction in contraceptive effectiveness. They measure drug concentrations, not pregnancy rates.
Does Mounjaro make birth control pills ineffective?
The available evidence does not establish that all birth control pills become ineffective during Mounjaro treatment.
The EMA’s announcement does not provide a numerical estimate of contraceptive failure or an increased pregnancy rate attributable to the interaction.
Instead, the concern is that the reliability of oral contraception may be reduced in some circumstances, particularly when tirzepatide is started or its dose is increased.
The recommendation to use a barrier method temporarily, or switch to non-oral contraception, is intended to address this uncertainty.
Patients should not assume that their contraceptive pill has stopped working, but neither should they ignore the new precaution if they are relying on it to prevent pregnancy.
Which contraceptive methods are affected?
The EMA’s communication specifically concerns oral contraceptives, meaning contraceptive medicines taken by mouth.
Non-oral contraception avoids the particular concern about absorption through the gastrointestinal tract.
Depending on individual medical circumstances, non-oral options may include:
- intrauterine devices or systems;
- contraceptive implants;
- contraceptive injections; and
- other suitable non-oral hormonal methods.
These methods differ in effectiveness, suitability, duration and potential adverse effects.
Patients should discuss their options with a clinician or contraception service rather than changing methods independently.
Barrier methods, including condoms, can provide temporary additional contraception during the four-week periods specified by the EMA.
Why does the warning matter during dose escalation?
Mounjaro treatment generally begins at a low dose, with gradual increases intended to improve tolerability.
Gastrointestinal effects, including nausea and vomiting, are particularly common during tirzepatide dose escalation.
The medicine’s effect on gastric emptying is also especially relevant around treatment initiation, and the new contraception advice specifically covers subsequent dose increases.
This means patients may encounter the four-week precaution more than once during the early stages of treatment.
For example, a patient who begins Mounjaro and later moves to a higher dose should consider the additional four-week period after that increase, even if the first four-week period has already ended.
Our Mounjaro side-effects guide explains the broader safety profile of tirzepatide, including gastrointestinal reactions and other recognised precautions.
What if someone vomits after taking the contraceptive pill?
Vomiting and severe diarrhoea can independently affect the reliability of some oral contraceptives because the medicine may not be adequately absorbed.
This is a separate consideration from the potential interaction between tirzepatide and oral contraceptive absorption.
People who experience vomiting or diarrhoea while taking Mounjaro should follow the missed-pill and gastrointestinal illness instructions for their specific contraceptive product.
The appropriate advice can differ between combined oral contraceptives and progestogen-only pills.
A pharmacist or contraception service can advise whether additional protection or emergency contraception should be considered based on the circumstances.
How does the new EU advice compare with the UK and Australia?
The November 2026 EMA communication brings European advice closer to precautions already communicated in other major regulatory markets.
United Kingdom
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) published guidance in June 2025 addressing GLP-1 medicines, contraception and pregnancy.
UK advice includes additional contraception precautions for people using tirzepatide alongside oral contraceptives, particularly after treatment initiation and dose increases.
Australia
Australia’s Therapeutic Goods Administration (TGA) published updated contraception advice for Mounjaro on 1 December 2025.
Following its safety investigation, the TGA concluded that reduced effectiveness of oral contraceptives during initiation or dose escalation could not be ruled out.
Australian product information was updated to advise switching to non-oral contraception or adding a barrier method for four weeks after starting tirzepatide and four weeks after each dose increase.
European Union
The EMA’s CHMP adopted the new direct healthcare professional communication during its November 2026 meeting.
The communication is intended to provide consistent advice to healthcare professionals across EU member states following the relevant European Commission decision.
The EMA has not stated that the communication has already been distributed to all healthcare professionals.
What about Mounjaro and pregnancy?
Contraception is particularly important because tirzepatide is not recommended during pregnancy.
European product information notes that human pregnancy data are absent or limited and that animal studies have identified reproductive toxicity.
Women who are pregnant, think they may be pregnant or are planning a pregnancy should seek medical advice about Mounjaro treatment.
European product information advises stopping tirzepatide at least one month before a planned pregnancy because of the medicine’s long half-life.
Patients should not interpret the new contraception warning as evidence that tirzepatide itself causes pregnancy or increases fertility. The concern addressed by the EMA is the potential reliability of oral contraception while using the medicine.
What should patients taking Mounjaro and the pill do now?
Women who rely on oral contraception and are starting Mounjaro, or expecting a dose increase, should review their contraceptive arrangements with their prescribing clinician or pharmacist.
Practical considerations include:
- Check whether your contraception is oral or non-oral. The EMA’s new precaution specifically concerns oral contraceptives.
- Plan for four weeks of additional barrier contraception after starting tirzepatide and after each dose increase, unless using an appropriate non-oral method.
- Ask before changing contraception. Switching methods can require careful timing to avoid gaps in protection.
- Seek advice about vomiting, diarrhoea or missed pills. These circumstances can introduce additional contraceptive concerns.
- Discuss possible pregnancy promptly. Mounjaro is not recommended during pregnancy, and individual medical advice is important.
Anyone concerned about recent unprotected intercourse, contraceptive failure or a possible pregnancy should seek timely advice from a pharmacist, contraception service or other qualified healthcare professional.
Frequently asked questions
Can I take the contraceptive pill while using Mounjaro?
The EMA has not announced a blanket prohibition on combining Mounjaro with oral contraceptives. However, it advises adding a barrier method for four weeks after starting tirzepatide and after each dose increase, or switching to non-oral contraception.
How long do I need extra contraception after starting Mounjaro?
The new EU recommendation specifies four weeks after starting Mounjaro and four weeks after every subsequent dose increase.
Does the warning apply to every Mounjaro dose?
The precaution applies when treatment begins and when the dose is increased. The EMA announcement does not describe a new four-week precaution for every injection taken at an unchanged dose.
Does Mounjaro reduce birth control effectiveness by 60%?
No such conclusion can be drawn from the available evidence. Some pharmacokinetic measurements showed large reductions in peak blood concentrations of contraceptive hormones, but these are not measurements of contraceptive failure rates.
Does the warning apply to contraceptive implants or IUDs?
The specific concern involves oral contraceptive absorption. The EMA advises that switching to non-oral contraception is an alternative to using an additional barrier method. Individual method suitability should be discussed with a healthcare professional.
Is the new warning already legally in force across the EU?
The EMA’s CHMP adopted a direct healthcare professional communication in November 2026. The EMA says the communication will be disseminated after a European Commission decision. The committee announcement should not be confused with confirmation that the communication has already been formally distributed.
Can Mounjaro be used during pregnancy?
Tirzepatide is not recommended during pregnancy. Patients who are pregnant or planning pregnancy should discuss treatment with their clinician. European product information advises stopping tirzepatide at least one month before a planned pregnancy.
What happens next?
The EMA says the direct healthcare professional communication will be distributed by Mounjaro’s marketing authorisation holder after a European Commission decision.
The communication will also be published on the EMA website and in national registers across EU member states.
Further regulatory updates may clarify how the advice is reflected in European prescribing information and national patient guidance.
For now, the main practical message is that women relying on oral contraception should account for the four-week precaution when starting Mounjaro or increasing its dose.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed the EMA’s November 2026 CHMP announcement, European Mounjaro product information and relevant UK and Australian regulatory guidance. Pharmacokinetic findings are distinguished from demonstrated contraceptive failure, and the status of the pending European healthcare-professional communication is identified.
Last reviewed: 14 November 2026
Sources and verification
- European Medicines Agency: CHMP meeting highlights, 9–12 November 2026 — primary source for the new EU contraception advice.
- European Medicines Agency: Mounjaro product information — pharmacokinetic interaction data and pregnancy precautions.
- Therapeutic Goods Administration: Updated contraception advice for Mounjaro, 1 December 2025 — Australian regulatory position.
- UK Medicines and Healthcare products Regulatory Agency: GLP-1 medicines for weight loss and diabetes — what you need to know — UK contraception and pregnancy guidance.
This article provides general information and does not replace individual medical advice. Mounjaro is a prescription medicine. Contraceptive choice, pregnancy planning, medication interactions and treatment changes should be discussed with an appropriate healthcare professional. Regulatory advice may change as further evidence becomes available.